<DOC>
	<DOCNO>NCT02704299</DOCNO>
	<brief_summary>Evaluate feasibility , safety efficacy Surgery，Chemotherapy Combination Autologous T cells-Based Immunotherapy Advanced Gastric Cancer .</brief_summary>
	<brief_title>The Study Surgery , Chemotherapy Autologous T Cells-Based Immunotherapy Advanced Gastric Cancer .</brief_title>
	<detailed_description>Safety : AE/SAE Efficacy : immunologic function ; FPS</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Aged 18 80 year , male female . Subjects understand sign consent form study . The pathologically confirm advanced gastric cancer T3、T4 T2 Metastasis lymph node . Subjects surgical candidate . No distant metastasis ( M0 ) No distant lymph node metastasis . Expected survival time least 6 month . Subjects sign consent form study . The subject allergic history medicine food . The subject uncontrolled hardtocontrol disease cardiovascular , liver , kidney lung , endocrine system . The subject test positive : HIV , hepatitis virus , syphilis infectious disease . The subject history malignant tumour . The subject history alcoholism , drug abuse , mental illness 12 year prior trial . The subject participate clinical trial 3 month prior trial . The subject pregnant , lactate plan conceive within next 24 month . The subject unsuitable adverse condition determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>